|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ischemic colitis:Clinical practice in diagnosis and treatment显示文摘Ischemic colitis is the most common form of ischemic injury of the gastrointestinal tract and can present either as an occlusive or a non-occlusive form. It accounts for 1 in 1000 hospitalizations but its incidence is underesti- mated because it often has a mild and transient nature. The etiology of ischemic colitis is multifactorial and the clinical presentation variable. The diagnosis is based on a combination of clinical suspicion, radiographic, endo- scopic and histological findings. Therapy and outcome depends on the severity of the disease. Most cases of the non-gangrenous form are transient and resolve spontaneously without complications. On the other hand, high morbidity and mortality and urgent operative intervention are the hallmarks of gangrenous ischemic colitis. | Angeliki Theodoropoulou Ioannis E Koutroubakis | 2008 | World Journal of Gastroenterology2008，14，48： | 75 |
| 2 | Multipotent role of platelets in inflammatory bowel diseases:A clinical approach显示文摘There is evidence that inflammatory bowel diseases(IBD)combine both inflammation and coagulation in their pathogenesis and clinical manifestations.Although platelets(PLT)are well known for their role in hemo stasis,there are a rising number of studies supporting their considerable role as inflammatory amplifiers in chronic inflammatory conditions.IBD are associated with several alterations of PLT,including number shape,and function,and these abnormalities are main ly attributed to the highly activated state of circulating PLT in IBD patients.When PLT activate,they increase in size,release a great variety of bio-active inflamma tory and procoagulant molecules/particles,and express a variety of inflammatory receptors.These inflamma tory products may represent a part of the missing link between coagulation and inflammation,and can be considered as possible IBD pathogenesis instigators.In clinical practice,thrombocytosis is associated both with disease activity and iron deficiency anemia.Controlling inflammation and iron replacement in anemic patient usually leads to a normalization of PLT count.The aim of this review is to update the role of PLT in IBD and present recent data revealing the possible therapeutic implications of anti-PLT agents in future IBD remedies. | Evangelos Voudoukis Konstantinos Karmiris Ioannis E Koutroubakis | 2014 | World Journal of Gastroenterology2014，20，12： | 27 |
| 3 | Thrombosis and inflammatory bowel disease-the role of genetic risk factors显示文摘Thromboembolism is a significant cause of morbidity and mortality in patients with inflammatory bowel dis-ease (IBD). Recent data suggest thromboembolism as a disease-specific extraintestinal manifestation of IBD, which is developed as the result of multiple interac- tions between acquired and genetic risk factors. There is evidence indicating an imbalance of procoagulant, anticoagulant and fibrinolitic factors predisposing in thrombosis in patients with IBD. The genetic factors that have been suggested to interfere in the thrombotic manifestations of IBD include factor Leiden, factor (prothrombin, G20210A), methylenetetrahydrofolate reductase gene mutation (MTHFR, 6777T), plasminogen activator inhibitor type 1 (PAI-1) gene mutation and fac- tor (val34leu). In this article we review the current data and future prospects on the role of genetic risk factors in the development of thromboembolism in IBD. | Georgia Tsiolakidou Ioannis E Koutroubakis | 2008 | World Journal of Gastroenterology2008，14，28： | 9 |
| 4 | Stimulating erythropoiesis in inflammatory bowel disease associated anemia显示文摘Anemia is a frequent complication in patients with inflammatory bowel disease (IBD), and is associated with decreased quality of life and increased rate of hospitalization. The primary therapeutic targets of IBD- associated anemia are iron deficiency and anemia of chronic disease. An important prognostic parameter of the success or failure of therapy is the outcome of the underlying disease. Iron deficiency should be appropriately managed with iron supplementation. However, the use of oral iron therapy is limited by several problems, the most important being gastrointestinal side effects leading occasionally to disease relapse and poor iron absorption. Intravenous iron preparations are more reliable, with iron sucrose demonstrating the best efficacy and tolerability. Treatment with erythropoietin or darbepoetin has been proven to be effective in patients with anemia, who fail to respond to intravenous iron. Patients with ongoing inflammation have anemia of chronic disease and may require combination therapy comprising of intravenous iron sucrose and erythropoietin. After initiating treatment, careful monitoring of hemoglobin levels and iron parameters is needed in order to avoid recurrence of anemia. In conclusion, anemia in the setting of IBD should be aggressively diagnosed, investigated, and treated. Future studies should define the optimal dose and schedule of intravenous iron supplementation and appropriate erythropoietin therapy in these patients. | Georgia Tsiolakidou Ioannis E Koutroubakis | 2007 | World Journal of Gastroenterology2007，13，36： | 5 |
| 5 | Is there a role for Tc-99m (V) DMSA scintigraphy in ischemic colitis?显示文摘AIM: To evaluate the role of pentavalent Tc-99m dimercaptosuccinic acid [Tc-99m (V) DMSA] in the diagnosis of ischemic colitis. METHODS: Fourteen patients with endoscopically and histologically confirmed ischemic colitis were included in the study. Tc-99m (V) DMSA scintigraphy was performed within 2 d after colonoscopy. Images were considered positive when an area of increased activity was observed in the region of interest and negative when no abnormal tracer uptake was detected. RESULTS: In 3 out of the 14 patients, Tc-99m (V) DMSA images showed moderate activity in the bowel. The scintigraphic results corresponded with the endoscopic findings. In the other 11 patients, no abnormal tracer uptake was detected in the abdomen. CONCLUSION: Besides the limited number of patients, Tc-99m (V) DMSA could not be considered as a useful imaging modality for the evaluation of ischemic colitis. | Maria I Stathaki Ioannis E Koutroubakis Sophia I Koukouraki Elias A Kouroumalis Nikolaos S Karkavitsas | 2008 | World Journal of Gastroenterology2008，14，35： | 4 |
| 6 | Recent advances in the management of distal ulcerative colitis显示文摘The most frequent localization of ulcerative colitis(UC) is the distal colon.In treating patients with active distal UC,efficacy and targeting of the drug to the distal colon are key priorities.Oral and rectal 5-aminosalicylic acid(5-ASA) preparations represent the first line therapy of mild-to-moderate distal UC for both induction and maintenance treatment.It has been reported that many UC patients are not adherent to therapy and that noncompliant patients had a 5-fold risk of experiencing a relapse.These findings led to the introduction of oncedaily oral regimens of 5-ASA as better therapeutic options in clinical practice due to improved adherence.New formulations of mesalazine,including the multimatrix delivery system,and mesalazine granules,which allow once-daily administration,have been developed.They have been demonstrated to be efficacious in inducing and maintaining remission in mild-to-moderate distal UC in large clinical trials.However,existing data for distal UC are rather insufficient to make a comparison between new and classical 5-ASA formulations.It seems that the new formulations are at least as effective as classical oral 5-ASA formulations.Other treatment options,in the case that 5-ASA therapy is not effective,include systemic corticosteroids,thiopurines(azathioprine or 6-mercaptopurine),cyclosporine,infliximab and surgery.The combination of a prompt diagnostic work-up,a correct therapeutic approach and an appropriate follow-up schedule is important in the management of patients with distal UC.This approach can shorten the duration of symptoms,induce a prolonged remission,improve patient's quality of life,and optimize the use of health resources. | Ioannis E Koutroubakis | 2010 | World Journal of Gastrointestinal Pharmacology and Therapeutics2010，1，2： | 3 |
| 7 | Solid extraintestinal malignancies in patients with inflammatory bowel disease显示文摘Malignancies constitute the second cause of death in patients with inflammatory bowel diseases(IBD),after cardiovascular diseases.Although it has been postulated that IBD patients are at greater risk of colorectal cancer compared to the general population,lately there has been evidence supporting that this risk is diminishing over time as a result of better surveillance,while the incidence of extraintestinal cancers(EICs)is increasing.This could be attributed either to systemic inflammation caused by IBD or to long-lasting immunosuppression due to IBD treatments.It seems that the overall risk of EICs is higher for Crohn’s disease patients and it is mainly driven by skin cancers,and liver-biliary cancers in patients with IBD and primary sclerosing cholangitis.The aims of this review were first to evaluate the prevalence,characteristics,and risk factors of EICs in patients with IBD and second to raise awareness regarding a proper surveillance program resulting in early diagnosis,better prognosis and survival,especially in the era of new IBD treatments that are on the way. | Anastasia Mala Kalliopi Foteinogiannopoulou Ioannis E Koutroubakis | 2021 | World Journal of Gastrointestinal Oncology2021，13，12： | 2 |
| 8 | Increased serum levels of YKL-40 in patients with inflammatory bowel disease显示文摘 | Ioannis E. Koutroubakis Efthymia Petinaki Philippos Dimoulios Emmanouel Vardas Maria Roussomoustakaki Antonios N. Maniatis Elias A. Kouroumalis | 2003 | International Journal of Colorectal Disease2003，，3： | 2 |
| 9 | Mean platelet volume: a useful marker of inflammatory bowel disease activity显示文摘 | Andreas N Kapsoritakis Michael I Koukourakis Aekaterini Sfiridaki Spiros P Potamianos Maria G Kosmadaki Ioannis E Koutroubakis Elias A Kouroumalis | 2001 | The American Journal of Gastroenterology2001，，3： | 2 |
| 10 | Spectrum of non-inflammatory bowel disease and non-infectious colitis显示文摘A variety of inflammatory diseases of the colon, which can be differentiated from inflammatory bowel disease (IBD) and infectious colitis by their clinical, endoscopic and histological characteristics, are reported as non- IBD and non-infectious colitis. These diseases include microscopic colitis, ischemic colitis, segmental colitis associated with diverticula, radiation colitis, diversion colitis, eosinophilic colitis and Behcet's colitis. The etiopathogenesis of most of these diseases remains obscure and the epidemiological data are rather limited. These conditions are often troublesome for the patient and are associated with diagnostic difficulties for the physician. In many cases the treatment is empirical and there is a need for future research using randomized controlled trials. | Ioannis E Koutroubakis | 2008 | World Journal of Gastroenterology2008，14，48： | 2 |
| 11 | Somatostatin for acute severe bleeding from portal hypertensive gastropathy显示文摘 | Kouroumalis EA Koutroubakis IE Manousos ON | 1998 | Eur J Gastroenterol Hepatol1998，10，： | 1 |
| 12 | Allelic polymorphism in IL-1β and IL-1 receptor antagonist(IL-1Ra) genes in inflammatory bowel disease显示文摘 | Bioque G Crusius JB Koutroubakis I | 1995 | Clin Exp Immunol1995，102，2： | 1 |
| 13 | Allelic polymorphism in IL-1 beta and IL-1 recep- tor antagonist (IL-1Ra) genes in inflammatory bowel disease显示文摘 | BIOQUE G CRUSIUS J B KOUTROUBAKIS I | 1995 | Clin Exp Immunol1995，102，： | 1 |
| 14 | Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease显示文摘 | Evangelos Voudoukis Konstantinos Karmiris Pantelis Oustamanolakis Angeliki Theodoropoulou Aekaterini Sfiridaki Gregorios A. Paspatis Ioannis E. Koutroubakis | 2013 | European Journal of Gastroenterology & Hepatology2013，，10： | 1 |
| 15 | New de- sensitization regimen with mesalamine granules in a pa- tient with ulcerative colitis and mesalamine intolerance 显示文摘 | Oustamanolakis Pantelis MD Koutroubakis | 2011 | Inflamm Bowel Dis2011，17，2： | 1 |
| 16 | Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease显示文摘 | Oustamanolakis P Koutroubakis IE Messaritakis I | | 0，，4： | 1 |
| 17 | Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease显示文摘 | Efstratios Koutroumpakis Georgia Tsiolakidou Ioannis Koutroubakis | 2013 | Semin Thromb Hemost2013，，： | 1 |
| 18 | Circulating soluble vascular adhesion,protein 1 in patients with inflammatory bowel disease显示文摘 | Koutroubakis IE Petinaki E Vardas E | 2002 | Eur J Gastroenterol Hepatol2002，14，： | 1 |
| 19 | Allelic polymorphism in IL-113and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease显示文摘 | Bioque G Crusius JBA Koutroubakis I | 1995 | Clin Exp Immunol1995，102，2： | 1 |
| 20 | Antibodies against eyclie citrul- linated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations 显示文摘 | Koutroubakis IE Karmiris K Bourikas L | 2007 | Inflammatory Bowel Diseases2007，13，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员